After 4 to 6 weeks of data, clear patterns emerge
This is especially helpful with retatrutide's triple-agonist mechanism which can cause stronger GI effects
Preliminary data published in June 2023 also suggests that GLP-1 drugs 'could modulate crucial pathways in the pathogenesis of inflammatory bowel disease (IBD), such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity' (Arvanitakis, Theocharis, Popovic
That is nearly one-fifth of total body weight gone in six months
Days 2-4: The Adjustment Phase What to expect: This is when most side effects appear
The patch uses SMGT (Sustained Micro-Gradient Technology) to deliver GLP-1 through a network of painless microneedles that gently penetrate the upper layer of the skin